PTO/SB/08A (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a coflection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 2

Complete if Known

Application Number 10/640,989

Filing Date August 14, 2003

First Named Inventor YANG

Art Unit 1651

Examiner Name

Attorney Docket Number 5853-261

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (# known)}			
		US-	j		
		US-		<u>-</u>	
		US-			
		US-	1		
		US-			
		US-			
	 -	US-			

		FORE	IGN PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY	,,	Or Relevant Figures Appear	T⁰
leb		WO 00/50048-A2	08/31/2000	UNIVERSITY OF PITTSBURGH		
						L
						┡
						<u> </u>
	l	l	l			$oldsymbol{ol}}}}}}}}}}}}}}}}}$

Examiner Signature	wa/h	Date Considered	8/3/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a valid OMB control number.

Substitute for form			O TOQUICO TO TOOPOTO TO O CONCUENTO	Complete if Known
Substitute for form	1449/210		Application Number	10/640,989
INFORM	ATION DIS	CLOSURE	Filing Date	August 14, 2003
STATEM	ENT BY A	PPLICANT	First Named Inventor	YANG
			Art Unit	1651
(Use a	as many sheets as n	ecessary)	Examiner Name	
Sheet 2	of	2	Attorney Docket Number	5853-261

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
leb		YAMAOKA, T. et al.: Development of Pancreatic Islets. International Journal of Molecular Medicine. 1999, Vol. 3, No. 3, pages 247-261	
		·	
		·	

Examiner	abzent L	Date	8/3/25
Signature VV C	100011	Considered	01-703

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	by the Paperwork Reduction Act of 1995, no persons of 1995, no pers			Complete if Known			
-edosiiu	Peassurae for form 1449/PTO			Application Number	10/640,989		
INFORMATION DISCLOSURE				Filing Date	August 14, 2003		
STA	STATEMENT BY APPLICANT			First Named Inventor	YANG		
	44			Art Unit	1651		
	(Use as many sheets as necessary)			Examiner Name			
Sheet	1	of	3	Attorney Docket Number	5853-261		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
leb		BUSCHARD et al., "Neonatal treatment with beta-cell stimulatory agents reduces the incidence of diabetes in BB rats," Int. J. Exp. Diabetes Res. 1:1-8, 2000.	
		HOHMEIER et al., "ISOLATION OF INS-1-DERIVED CELL LINES WITH ROBUST ATP-SENSITIVE K+ CHANNEL-DEPENDENT AND-INDEPENDENT GLUCOSE-STIMULATED INSULIN SECRETION," Diabetes 49: 424-430, 2000.	
		SHAPIRO et al., "Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen," N. Engl. J. Med. 343:230-238, 2000.	
		YANG et al., "In Vitro trans-differentiation of adult hapatic stem cells into pancreatic endocrine hormone-producing cells.," PNAS 99:8078-8083, 2002.	
		DEUTSCH et al., "A bipotential precursor population for pancreas and liver within the embryonic endoderm," Development 128:871-881, 2001.	
		REYES et al., "Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells," Blood 98:2615-2625, 2001.	
		BONNER-WEIR, "In vitro cultivation of human islets from expanded ductal tissue," PNAS 97:7999-8004, 2000.	
		RAMIYA et al., "Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells," Nat.Med. 6:278-282, 2000.	
		IANUS et al., "In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion," J.Clin.Invest 111:843-850, 2003.	
V		RAJAGOPAL et al., "Insulin Staining of ES Cell Progeny from Insulin Uptake," Science 299:363, 2003.	

Examiner Signature	(DA)	 Date Considered	8/3/05

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) and for use through 07/31/2006. OMB 0651-0031

	Approved for any amongs on a masses. Office occurrence
	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paneount's Reduction Art of 1995, no persons are required to resi	rond to a collection of information unless it contains a valid OMB control number

	ite for form 1449/PTO		,		Complete if Known		
Substitute for form 1449/PTO				Application Number	10/640,989		
INF	ORMATION	DIS	CLOSURE	Filing Date	August 14, 2003		
STA	ATEMENT B	Y A	PPLICANT	First Named Inventor	YANG		
	// to a	-4		Art Unit	1651		
İ	(Use as many she	ets as i	ecessary)	Examiner Name			
Sheet	2	of	3	Attorney Docket Number	5853-261		

			NON PATENT LITERATURE DOCUMENTS	
Exan Initia	niner ls*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	eb		XU et al., "Exendin-4 Stimulates Both Beta-Cell Replication and Neogenesis, Resulting in Increased Beta-Cell Mass and Improved Glucose Tolerance in Diabetic Rats," Diabetes 48:2270-2276, 1999.	
			AKIYAMA et al., "Activation of Reg gene, a gene for insulin-producing beta-cell regeneration: Poly(ADP-ribose) polymerase binds Reg promoter and regulates the transcription by autopoly (ADP-ribosyl)ation. PNAS 98:48-53, 2001.	
			KOJIMA et al., "NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice," Nature Medicine 9:596-603, 2003.	
			CORNELIUS et al., "In vitro-generation of islets in long-term cultures of pluripotent stem cells from adult mouse pancreas," Horm Metab. Res. 29: 271-277, 1997.	
			LUMELSKY et al., "Differentiation of Embryonic Stem Cells to Insulin-Secreting Structures Similar to Pancreatic Islets," Science 292:1389-1394, 2001.	
			ASSADY et al., "Insulin Production by Human Embryonic Stem Cells," Diabetes 50:1691-1697, 2001.	
			PETERSEN et al., "Bone Marrow as a Potential Source of Hepatic Oval Cells," Science 284:1168-1170, 1999.	
			OTONKOSKI et al., "Nicotinamide is a potent inducer of endocrine differentiation in cultured human fetal pancreatic cells," J. Clin. Invest, 92:1459-1466, 1993.	
			SORIA et al., "From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus," Diabetologia 44:407-415, 2001.	
J			ZULEWSKI et al., "Multipotential Nestin-Positive Stem Cells Isolated From Adult Pancreatic Islets Differentiate Ex Vivo Into Pancreatic Endocrine, Exocrine, and Hepatic Phenotypes," Diabetes 50:521-533, 2001.	

	Examiner Signature	hV	Date Considered	8/3	105
--	-----------------------	----	--------------------	-----	-----

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) for use through 07/31/2006. OMB 0651-0031

	Applied to the property of the con-	
	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COM	
Under the Paperwork Reduction Act of 1995, no persons an	e required to respond to a collection of information unless it contains a valid OMB control	number.
	Complete if Known	
titute for form 1449/PTO	,	

Substitute for form 1449/PTO				Complete if Known		
Substitute to form 1443/F10				Application Number	10/640,989	
INFORMATION DISCLOSURE				Filing Date	August 14, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	YANG	
(Use as many sheets as necessary)				Art Unit	1651	
			necessary)	Examiner Name		
Sheet	3	of	3	Attorney Docket Number	5853-261	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite Initials* No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of			
lev		SJOHOLM et al. "Role of polyamines in mitogenic and secretory responses of pancreatic beta-cells to growth factors," Am J. Physiol. 259:C828-C833, 1990.			
		VOGEL, "Same Results, Different Interpretations," Science 299:324, 2003.			
		HESS et al., "Bone-marrow-derived stem cells initiate pancreatic regeneration," Nature Biotechnology 21:763-770, 2003.			
		DENG et al., "Neural trans-differentiation potential of hepatic oval cells in the neonatal mouse brain," Experimental Neurology 182:373-382, 2003.			
\bigvee		HELLERSTROM et al., "Functional Maturation and Proliferation of Fear Pancreatic B-Cells," Diabetes 40:89-93, 1991.			
14					

Examiner	in all	Date	5/2/1
Signature	10 W/2 -0	Considered	0/5/03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of finis form with next communication to applicants to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.